Tumor necrosis factor receptor 2 (TNFR2) signaling is negatively regulated by a novel, carboxyl-terminal

Adrian P Grech1, Sandra Gardam, Tyani Chan

  • 1Centenary Institute of Cancer Medicine and Cell Biology, Locked Bag No. 6, Newtown, New South Wales 2042, Australia.

Insights

Tumor necrosis factor receptor 2 (TNFR2) has a hidden site that dampens its signaling. This site, T2bs-C, controls how TNFR2 activates NF-kappaB and JNK pathways.

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Biology

Background:

  • Tumor necrosis factor (TNF) superfamily receptors typically activate NF-kappaB and JNK pathways via TRAF2 recruitment.
  • Type 2 TNF receptor (TNFR2) poorly activates these pathways despite robust TRAF2 binding.

Purpose of the Study:

  • To resolve the paradox of TNFR2's poor signaling despite high TRAF2 binding.
  • To elucidate the mechanism by which TNFR2 regulates NF-kappaB and JNK activation.

Main Methods:

  • Site-directed mutagenesis to inactivate specific TRAF2-binding sites (T2bs-N and T2bs-C) within TNFR2.
  • Assessment of TRAF2 recruitment to TNFR2.
  • Measurement of ligand-dependent NF-kappaB and JNK pathway activation.

Main Results:

  • TNFR2 possesses a novel carboxyl-terminal TRAF2-binding site (T2bs-C) that attenuates signaling.
  • Inactivating T2bs-N reduced TRAF2 recruitment but did not affect NF-kappaB/JNK activation.
  • Inactivating T2bs-C enhanced NF-kappaB/JNK activation without altering TRAF2 recruitment levels.

Conclusions:

  • TNFR2's T2bs-C acts dominantly to attenuate signaling from the T2bs-N site by a mechanism independent of TRAF2 recruitment.
  • This uncoupling of TRAF2 recruitment and signaling in TNFR2 may regulate signaling in conjunction with TNFR1.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...